Hartl Brad A, Hirschberg Henry, Marcu Laura, Cherry Simon R
Department of Biomedical Engineering, University of California, Davis, Davis, CA 95616, USA.
Beckman Laser Institute and Medical Clinic, University of California, Irvine, Irvine, CA 92697, USA.
Biomed Opt Express. 2015 Feb 10;6(3):770-9. doi: 10.1364/BOE.6.000770. eCollection 2015 Mar 1.
The translation of photodynamic therapy (PDT) to the clinic has mostly been limited to superficial diseases where traditional light delivery is noninvasive. To overcome this limitation, a variety of mechanisms have been suggested to noninvasively deliver light to deep tissues. This work explores the minimum amount of light required by these methods to produce a meaningful PDT effect in the in vitro setting under representative low fluence and wavelength conditions. This threshold was found to be around 192 mJ/cm(2) using the clinically approved photosensitizer aminolevulinic acid and 12 mJ/cm(2) for the more efficient, second generation photosensitizer TPPS2a.
光动力疗法(PDT)向临床的转化大多局限于传统光传输为非侵入性的浅表疾病。为克服这一局限性,人们提出了多种将光非侵入性传输至深部组织的机制。这项研究探讨了在具有代表性的低能量密度和波长条件下,这些方法在体外环境中产生有意义的PDT效应所需的最小光量。使用临床批准的光敏剂氨基乙酰丙酸时,该阈值约为192 mJ/cm²,而对于效率更高的第二代光敏剂TPPS2a,该阈值为12 mJ/cm²。